Uterine Sarcoma Market 2019–By Identifying The Key Market Segments And Key Players Holding Market Share

Market Scenario:

Sarcomas are the tumours of the mesenchymal tissues like bone, muscle, connective tissue, cartilage and fat. Uterine sarcoma is a rare type of cancer which starts in the muscle and supporting tissues of the uterus. Exposure to the X-rays increases the risk for uterine sarcoma. Unusual vaginal bleeding, spotting, or discharge are some of the common symptoms for the disease. Increasing prevalence of the uterine sarcoma and growing female geriatric population are the major drivers for the market growth during the forecast period, 2017-2023. In 2017, according to the American Cancer Society, 4,910 new cases of uterine sarcomas were reported in the U.S. Moreover, according to the World Bank, the female population which aged over 65 years rose from 316.27 billion to 347.25 billion in 2016.

Additionally, rising healthcare expenditures and increasing awareness regarding women health is expected to boost the market growth. However, high cost of treatment and related side effects are the factors that can restrain the market growth. Chemotherapy is extensively exploited for the therapeutics of the uterine sarcoma. Some of the side effects of the chemotherapy are inclusive of hair loss, anemia, reduced fertility, and others.

The global uterine sarcoma market size is expected to grow at an approximate CAGR of 8.5% from 2017 to 2023.

Key players

• Pfizer Inc.
• Intas Pharmaceuticals Ltd.
• FMC Corporation
• Sun Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.
• General Electric Company
• Koninklijke Philips N.V.
• Siemens Healthcare Private Limited

Segmentation

The global uterine sarcoma market is segmented on the basis of type, diagnosis, treatment, and end user.

On the basis of the treatment, the market is segmented into surgery, radiotherapy, chemotherapy, hormone therapy, and others. The surgery segment is sub-segmented into bilateral salpingo-oophorectomy, hysterectomy, and others. The chemotherapy segment is sub-segmented into dacarbazine, docetaxel, doxorubicin, and others. The hormone therapy segment is sub segmented into progestins, aromatase inhibitors, and others.

On the basis of the type, the market is segmented into uterine leiomyosarcoma (LMS), endometrial stromal sarcoma (ESS), undifferentiated sarcoma, and others.

On the basis of the diagnosis, the market is categorised into sampling & testing, imaging tests, and others. The sampling & testing segmented is sub-segmented into endometrial biopsy, dilation and curettage, cystoscopy and proctoscopy, and others. The imaging tests segment is sub segmented into transvaginal ultrasound, computed tomography, magnetic resonance imaging, positron emission tomography scan, and others.

On the basis of end users, the market is segmented into hospitals & clinics, academic institutes research organization, and others.

Regional Analysis

Asia Pacific region is also regarded to be the fastest growing market. Increasing awareness for women health and growing healthcare sector are the major drivers for the market growth within the region. Moreover, the presence of the developing countries like the India and China within the region fuels the market growth. According to the Indian Brand Equity Foundation in 2017, the Indian healthcare sector was one of the fastest growing industries in India and is expected to advance at a CAGR of 22.87% from 2015-2020.

America dominates the global uterine sarcoma market owing to increasing adoption of new technologies and huge patient population. Additionally, rising healthcare expenditure and presence of a developed healthcare sector within the region fuels the market growth.

Europe is the second largest market for uterine sarcoma owing to rising research and development in healthcare sector and huge patient population.  By region, Europe is divided into Western Europe and Eastern Europe. The presence of developed economies like France, Germany, Italy have made the Western Europe to lead the market within the region. On the other hand, Eastern Europe is the fastest growing region in Europe.

The Middle East & Africa has the least share in the global uterine sarcoma market due to presence of poor economies and stringent government policies, especially in the African region. Majority of the market of Middle & Africa region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure by the presence of the economies like Saudi Arabia, Kuwait and Qatar within the region.

Fungal Endocarditis Research Report And Overview On Fungal Endocarditis Market, 2019

Fungal endocarditis is an infection of the heart’s inner lining, known as the endocardium. The etiologic fungi more commonly observed are the Candida and Aspergillus species.

The gold standard for the diagnosis of fungal endocarditis is culture and the isolation of etiologic agents from infected valves, emboli, and other materials collected by different invasive methods such as surgery.

A number of factor such as rising incidents of fungal endocarditis, increasing awareness about fungal infections, improving regulatory framework, increasing government assistance, and rising funding and reimbursement are propelling the growth of the global fungal endocarditis market.

It is estimated that the fungal endocarditis market is expected to grow at a CAGR 4.2% during the forecast period of 2017-2023.

However, challenges in research and development, side-effects of treatment, presence of misbranded and spurious drugs and poor healthcare system in low and middle-income countries may hamper the growth of the market.

Key Players

Some of key the players in the global fungal endocarditis market are Pfizer, Merck & Co., Sanofi, Astellas Pharma, Inc., GlaxoSmithKline plc, Novartis AG, Enzon Pharmaceuticals, Inc., Bayer AG, Sigma-Aldrich, Abbott Laboratories, Eli Lily and Company, and Others. 

Segmentation

The global fungal endocarditis market is segmented on the basis of type of causative agent, diagnosis, treatment, and end-user.

On the basis of the treatment, the market is classified as antifungal medication, surgery, and combined treatment. The antifungal medication is further segmented into voriconazole, amphotericin B (AMB), itraconazole, caspofungin, echinocandins, and others.

On the basis of the type of causative agent, the market is segmented into Candida species

Aspergillus species, and Histoplasma capsulatum.

On the basis of the diagnosis, the market is classified into physical examination, blood test, X-ray, echocardiography, and electrocardiogram

On the basis of the end-users, the market is segmented into hospital, clinics, diagnostic centers, and others.

Regional Analysis

The Asia Pacific is the fastest growing fungal endocarditis market share owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.

The Americas dominate the fungal endocarditis market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

Europe holds the second position in the fungal endocarditis market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.

The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.

Acoustic Neuroma Market Research Report 2019 Analysis And Forecast To 2023

Market Scenario

Acoustic neuromas also known as vestibular schwannomas, usually grows slowly over a period of years. Usually they do not invade the brain, but can push on it as they grow. As the tumor grows, they press the nearby cranial nerves that control the muscles enabling facial expression and sensation. If the tumor becomes large enough to press on the brain stem or cerebellum, it can be deadly. They account for almost 8% of all tumors inside the skull. The prevalence rate is 1 out of every 100,000 individuals per year.

An acoustic neuroma is a non-cancerous (benign) growth that develops on the 8th cranial nerve (vestibulocochlear nerve), it connects the inner ear with the brain and has two different parts. One part is involved in transmitting sound and the other sends balance information to the brain.

Acoustic neuromas are mainly categorized into unilateral and bilateral vestibular schwannomas. Unilateral affect only one ear and bilateral vestibular schwannomas affect both hearing nerves and are usually associated with some genetic disorder. More than half of the affected individuals have inherited the disorder from an affected parent. Several new drugs are launched by the key players which grants various opportunities for the global acoustic neuroma market.

The global acoustic neuroma treatment market is expected to grow at a CAGR of approximately 7.6% during the forecast period 2017-2023.

Usually these neuromas are rare. Globally around 1-20 people in every million are diagnosed each year with an acoustic neuroma. Acoustic neuromas account for about 6 cases in every 100 patients with brain tumours. They are more common in middle-aged adults and are rare in children. Furthermore,  these neuromas seem to be more common in women than in men. Acoustic neuromas tend to affect adults aged 30 to 60 and usually have no obvious cause, although a small number of cases are the result of a genetic condition called neurofibromatosis type 2 (NF2).

The gadolinium enhanced magnetic resonance imaging (MRI) is the gold standard for diagnosis of vestibular schwannoma yet several examinations may arise suspicion of vestibular schwannomas. According to a patient survey held by the Acoustic Neuroma Association, in 2012, it was reported that after surgical treatment of acoustic neuroma more than 35% patients suffered a headache depending on the type of surgical approach, technique used and the time since surgery.

Top Key Acquisitions

Many new companies have jumped into the market in order to make the most out of the opportunities. Companies are implementing the strategies of mergers and acquisitions with other players.

Some of key the players in the global acoustic neuroma market are GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), F. Hoffmann-La Roche Ag, Merck & Co., Inc., Novartis AG, Pfizer Inc., and others

Segmentation

The acoustic neuroma is segmented on the basis of type, diagnosis, drug class, treatment, and end-users.

On the basis of type, the market is segmented into unilateral vestibular schwannomas and bilateral vestibular schwannomas.

On the basis of diagnosis, the market is segmented into hearing test (audiometry), electronystagmography, magnetic resonance imaging (MRI), and others.

On the basis of end-user, the market is segmented into hospitals, diagnostic centers, academic and research institutes, and others.

On the basis of drug class, the market is segmented into anticonvulsants, corticosteroids, osmotic diuretics and pain killers.

On the basis of treatment, the market is segmented into monitoring, surgery, radiation therapy, supportive therapy and others. The radiation therapy is sub segmented stereotactic radiotherapy, proton beam therapy. Surgery is sub segmented radiosurgery, craniotomy, and microsurgery removal

Regional Analysis

The global acoustic neuroma market consists of countries namely America, Europe, Asia Pacific, and the Middle East.

North America is projected to hold the largest share of the global acoustic neuroma market due to presence of huge numbers of key players supporting research and development for developing novel therapies, large base of diagnostic centers and greater emphasis on disease prevention and wellness by governments. Along with that healthcare facilities in the U.S. are gradually moving from treatment to wellness, so the prevention and early detection of disease is critical. Approximately 2,000 to 3,000 cases are diagnosed each year with acoustic neuroma in the United States (6 to 9 per million persons).

The European acoustic neuroma market hold the second largest market as it witness rapid growth. According to NHS U.K, an acoustic neuroma can occasionally return after treatment. This is thought to happen to around 1 in every 20 people who have had surgical removal.

Asia Pacific is expected to be the most promising markets for acoustic neuroma in the near future The Middle Eastern region is expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the health care sector.

Biological Computers Market 2019 Analysis, Opportunities And Forecast To 2023

Market Synopsis of the Global Biological computers Market

Biological computers are systems developed form basic components such as software, hardware, input and output. DNA and RNA are the basis of biological systems used as software for constructing the biological systems.

Prevalence of cancer such as lung cancer, mouth cancer, and bone cancer is on the rise across the globe, especially in the developing countries. The market is driven by the increasing prevalence of respiratory diseases in rural areas for developing countries. In addition, increasing research and development activities in the field of oncology, and technological advancements made to identify the causes and risk factors for chronic diseases have added fuel to the global biological computers market growth. Rising awareness about gene chip and other biological systems that can be used for cell transformation with the help of information technology also drives the market growth.

Biological computers, also known as DNA computers, are microcomputers designed for their use in the field of medicine. This implantable device can be used for various functions such as monitoring the activities of the body or inducing therapeutic effects. Hardware, software, input, and output are the four major components of a biological computer. These components are made of DNA, RNA and proteins. Biological computers are able to perform mathematical calculations that enable the researcher to construct a system of biosensors. This system of biosensors can detect or target specific types of cells such as cancer cells in the patient’s body.

As per the report of the Centers for Disease Control and Prevention (CDC), in 2014, over 14.1 million of new cancer cases were registered worldwide.

The global biological computers market is expected to grow at a CAGR of 7.1% during the forecast period 2017-2023.

Key Players   

• Microsoft (U.S.)
• IBM (U.S.)
• Thermofisher Scientific (U.S.)
• Illumina, Inc. (U.S.)
• IndieBio (U.S.)
• Emulate Inc. (U.S.)

Key Players manufactruing DNA or gene chips

• Sequenom Inc.
• Merck KGaA (U.S.)
• Macrogen Corp (Republic of Korea)
• Bioneer Corporation (Republic of Korea)
• Biometrix Technology Inc (U.S.)
• Wafergen Biosystems Inc. (U.S.)
• Eurofins Genomics India Pvt Ltd. (India)

Segmentation                                                                                                                                            

The global biological computers market is segmented on the basis of component, application, and end user.

On the basis of the component, market is segmented into hardware, software, input, and output.

On the basis of the application, the market is segmented into oncology, molecular genetics, nanobiotechnology, and others.

On the basis of the end user, the market is segmented into pharmaceutical & biotechnology companies, research centers, healthcare it companies, hospital & clinics, and others.

Regional Analysis   

The Americas hold the first position in the biological computers market owing to the rising prevalence of cancer in the U.S., and increasing demand for new cancer diagnostic and treatment services. In the Americas, North America is the largest market owing to the presence of key players in the healthcare IT industry.

Europe is the second largest market for biological computers. In Europe, there is an increasing demand for healthcare IT solutions and extensive research and development activities is taking place by clinical research and academic institutes for cancer treatment. According to Cancer Research UK, in 2014, 356,860 new cases of cancer were reported, including 579 cases of bone cancer.  

The market in Asia Pacific is expected to grow at the fastest pace and is driven by the high prevalence of chronic disease such as cancer, obesity, diabetes and other. India, China, and Japan are major contributors to the growth of the market. This growth is attributed to an increasing demand for technologically advanced medical devices and accessories such as gene chips for research activities. Availability of highly qualified medical professionals dedicated to research in biological systems is also a contributing factor. The various other factors affecting the growth of the market in Asia Pacific are rising geriatric population, demand for advanced therapies, government initiatives, and increasing public awareness about various diseases and the available treatments.

Additionally, healthcare spending in Asia Pacific expanded in 2016 due to an extension of state healthcare programs, and the increasing affluence of the population. Organization for Economic Co-operation and Development (ECOD) stated that growth in India will remain high at 7.3% in 2017.

The Middle East & Africa also show a steady rise in the market owing to low technological penetration and increasing awareness about cancer treatment. In the Middle East & Africa, Middle East captures the largest market share for biological medicines owing to the availability of better healthcare infrastructure and wide scope for research.

Heart Tumor Market Value Share, Supply Demand, Share And Value Chain 2019

Heart Tumor Market Scenario

According to the surgery and autopsy reports, primary cardiac tumors are rare with an incidence rate of about 0.3%-0.7%. Malignant primary cardiac sarcomas are usually located in the right atrium of the heart and are most commonly angiosarcomas. The malignant primary cardiac tumors are often diagnosed in young patientswho have a poor prognosis and survival rate of only 10% According to the WHO, the prevalence of melanoma skin cancers has been increasing from the past few decades. Furthermore, 132,000 melanoma skin cancers cases are reported each year across the globe.

The Global Heart Tumor Market is expected to grow at a CAGR of approximately 7.1% during the forecast period.

Cardiac tumors is a rare disease that are difficult to diagnose. They are divided on the basis of type into primary and secondary tumors. The prevalance of the secondary tumors is higher than the primary tumors. Majority of the primary cardiac tumors are benign in origin. The high incidences of metastatic tumors  is attributed to various types of  cancers such as lung, breast, renal cancer, lymphomas and melanomas. Clinical manifestations of these tumors generally based on  the size and location of the tumors and spread to the adjacent tissues rather than the type of the tumor itself.  Echocardiography is the major tool used for diagnosis of the tumors. Other imaging modalities include cardiac MRI, cardiac CT, and 3D echocardiography, which may offer some additional information with histological examination.

A small percentage of cardiac tumor cases are hereditary, the tumors can also be associated with another health condition, such as LAMB Syndrome, Carney Syndrome or NAME Syndrome. However, most often, the tumor develops without being associated with any health condition or presence of a family history. They result from cell overgrowth but mostly cardiac tumors results from metastatic condition, where cells from other cancerous organ such as lung and breast, soft-tissues and metastasizes to the heart.

Heart Tumor Market Key Players

Some of key the players in the Global cardiac tumor market are Tomtec Imaging Systems GmBh, Koninklijke Philips N.V., Siemens Healthineers, Circle Cardiovascular Imaging Inc., Toshiba Corporation, Shimadzu Corporation, CardioComm Solutions Inc., Integer Holdings Corporation, Pie Medical Imaging, HeartSciences, 3mensio Medical Imaging, and eMedica, S.L.

Heart Tumor Market Segmentation

The heart tumor is segmented on the basis of type, diagnosis, treatment.

On the basis of the type, the market is segmented into primary tumors and secondary tumors. The primary tumors are divided into benign and malignant. The benign tumors is further categorized into myxoma, papillary heart tumors, fibromas, rhabdomyomas, angioma, and lipomas. The malignant tumors are divided into rhabdomyosarcoma, mesenchymomas, neurosarcoma, fusiform cell tumors, malignant heart hemangioma, and lymphosarcoma. The secondary tumor is categorized into metastatic and contiguity. The metastatic secondary tumors are divided into hematogenic and lymphatic and the contiguity is sub categorized into mediastinal tumors, lung tumors and oesophageal, or cardia tumor.

On the basis of the diagnosis, the market is classified into echocardiogram, Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI), radionuclide imaging, Position Emission Tomography (PET) Scan, myocardial biopsy, cardiac catherization, and electrophysiology test.

On the basis of the treatment, the market is classified into surgery, chemotherapy, radiation therapy. Furthermore, the surgery is further categorized into open heart surgery, minimal invasive surgery, and heart transplant surgery 

International Heart Tumor Market Regional Analysis

The global heart tumor market consists of four major regions: the Americas, Europe, Asia Pacific, and the Middle East and Africa. The Americas dominate the market owing to the rising awareness among people and increasing healthcare expenditure. The type of tumors also aids in selection of treatment procedure. For instance, in patient with heart cancers, the results of cardiac imaging could be used to see if the the tumor is spread to the adjacent tissues, which can be further used to remove the portion by performing excision surgery or pursuing treatment with medications.

Encephalomalacia Market Volume Forecast And Value Chain Analysis 2019

Market Scenario

Softening or loss of brain tissue is termed as encephalomalacia and is a severe type of brain damage. Encephalomalacia disorder can also be classified into the three categories depending on their colors and the stages of damage i.e. red softening yellow softening, and white softening. The major causes of encephalomalacia are inflammation or hemorrhages that are a consequence of being afflicted by cerebral infarction, cerebral ischemia, infection, craniocerebral trauma, or another injury. Moreover, stroke is the most commonly known cause of encephalomalacia and stroke can be caused by either a head injury or a brain hemorrhage or both of them cause internal bleeding in brain. Furthermore, strokes occur due to reduced or interrupted blood supply to the brain, which is caused by blocked arteries or a burst blood vessel. Moreover, people with diabetes, blood sugar levels that become too high (hyperglycemia) or too low (hypoglycemia) which increases chances of strokes 

People who have been rescued from drowning or those who have been resuscitated after a heart attack may not awaken due to lack of oxygen to the brain. Furthermore infections such as encephalitis and meningitis cause swelling or inflammation of the brain, spinal cord or the tissues that surround the brain in severe cases of these infections can result in brain disorder.

Increasing prevalence of neurological disorders, increasing investment by biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods to boost to the Encephalomalacia market. Moreover, favorable reimbursement policies, increased application and significant investments in the development of new technologies for the treatment of diseases will fuel the market growth during the forecast period

Furthermore, globalization in healthcare has increased the market growth. Established market players in the developed countries leads the globalization by pushing new products and services into the developing countries and emerging economies. 

According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high-income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden, which is expected to increase further over the coming years.

However, limited availability of facilities and higher treatment cost may hamper the market growth during the forecast period.

The global encephalomalacia market is expected to grow at a CAGR of ~6.1% during the forecast period 2017-2023.

Key Players

Some of key the players in the market are Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Carestream Health (U.S.), Nihon Kohden Corporation (Japan), Electrical Geodesics Inc. (U.S.), Masimo Corporation (U.S.), Hologic (U.S.), Esaote (Italy), and others.

Segmentations

The global encephalomalacia market is segmented on the basis of types, diagnosis, treatment, and end user.

On the basis of the type, it is segmented into leukoencephalomalacia (encephalomalacia affecting the white matter), and polioencephalomalacia (encephalomalacia affecting the gray matter).  

On the basis of the diagnosis, it is segmented into blood test, brain scans, and others. A brain scan is further segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI) and electroencephalography (EEG).

On the basis of the treatment, it is segmented into medical treatment, surgery, and others.

On the basis of the end user, it is segmented into hospitals & clinics, research laboratories, and others.

Regional Analysis

The Americas dominate the global encephalomalacia market owing to well-developed technology, increasing prevalence of brain disorder, high health care spending, and increasing government support for research & development in the healthcare sector. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.

Europe holds the second position in the global encephalomalacia market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, developed economies such countries such as Germany and France are increasing investment in the healthcare domain and are focusing more on hospital infrastructure.     

The Asia Pacific is the fastest growing encephalomalacia market owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Moreover, increasing patient population in countries like India and South Korea are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region.   

On the other hand, the Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.

Spongiform Encephalopathy Market Growth And Restrain Factors Analysis By 2023

Market Scenario

Transmissible spongiform encephalopathy (TSEs) or prion diseases are a group of invariably fatal conditions that affect central nervous system (CNS) and more specifically the brain and spinal cord. The most commonly known prion diseases in human are Fatal Familial Insomnia, Creutzfeldt - Jakob disease (CJD), Gerstmann-Straussler-Scheinker Syndrome, and Kuru, and most commonly identified animal prion diseases are Transmissible mink encephalopathy, Bovine Spongiform Encephalopathy (BSE), Scrapie, and others.

BSE (bovine spongiform encephalopathy) is one of the most common neurological disorder found in cattle that results from a transmissible agent called a prion. According to the Centers for Disease Control and Prevention, five cases of BSE are found in the U.S. and 20 in Canada in 2017.

A number of factors such as rising facilities for patients affected by encephalopathy, increasing awareness among people, increasing government assistance, and improvement in regulatory framework are propelling the growth of the global spongiform encephalopathy market.

Despite these drivers, challenges in research and development, and poor healthcare system in low and middle-income countries may hamper the growth of the market.

It is estimated that spongiform encephalopathy market expected to grow at a healthy CAGR of 6.1% during the forecast period 2017-2023.

Key Players

Teva Pharmaceuticals, Abbvie, Adamas Pharmaceuticals, Inc., Newron Pharmaceuticals SPA, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Lonza, Merck KGaA, Thermo Fisher Scientific Inc., and others.

Regional Analysis

The Asia Pacific is the fastest growing spongiform encephalopathy market owing to the huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the year 2014-15.

Europe dominates the spongiform encephalopathy market owing to the high prevalence of bovine spongiform encephalopathy in European region, support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region

The Americas hold the second position in the spongiform encephalopathy market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the U.S. was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

The Middle East & Africa owns the least share of the global spongiform encephalopathy market due to lack of technical knowledge and poor medical facilities.

Segmentation

The spongiform encephalopathy market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of the type, the market is segmented into in humans, in animals. The human's segment is classified into Creutzfeldt-Jakob disease, Variant Creutzfeldt-Jakob disease (vCJD), others. The others segment includes Gerstmann-Sträussler-Scheinker disease, fatal familial insomnia, and kuru (Papua New Guinea). The animals segment is classified into bovine spongiform encephalopathy (BSE), Scrapie in sheep and goats, Chronic Wasting Disease (CWD), Feline spongiform encephalopathy, others. BSE is further classified into classical BSE and atypical BSE.

On the basis of the diagnosis, the market is classified into histopathology and immunohistochemistry, immunochemical detection methods, animal bioassays, cell culture assay systems, protein misfolding cyclic amplification, conformation-dependent immunoassay, capillary electrophoresis, fluorescent correlation spectroscopy, multispectral ultraviolet fluorescence spectroscopy, and Fourier transform infrared spectroscopy. Histopathology and Immunohistochemistry are further segmented into immunohistochemical staining and electron microscopy. Immunochemical Detection Methods is further segmented into Western Blotting Test, and Enzyme-Linked Immunosorbent Assay (ELISA).

On the basis of the treatment, the market is classified into small molecules, and immunotherapies. The small molecules are further classified into pentosan polysulfate, quinacrine, amphotericin B, and others. Immunotherapies are further classified into Antibody-based immunotherapies and Cell-Based Immunotherapies. Antibody-based immunotherapies include passive immunization, active immunization, and targeting disease-specific epitopes. Cell-based immunotherapies include DC vaccines and adoptive transfer of CD4+ T-cells.

On the basis of the end-users, the market is segmented into hospital & clinics, diagnostic centers veterinary hospitals, research & academic laboratories, and others.